ProQR Therapeutics NV expected to post a loss of 17 cents a share - Earnings Preview

ProQR Therapeutics NV

20/02/2023 17:16

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
22 (estimated). 
    * The Leiden Zuid-holland-based  company is expected to
report  a
115.4% increase in revenue to €956.32 thousand from €444
thousand a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ProQR Therapeutics
NV is
for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $3​, below​ its last closing price of $3.09.
​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.19       -0.21      -0.34     Missed  -62
 Jun. 30 2022  -0.22       -0.22      -0.21     Beat    2.7
 Mar. 31 2022  -0.24       -0.24      -0.20     Beat    15.1​
 Dec. 31 2021  -0.18       -0.19      -0.26     Missed  -40
 ​​Sep.        -0.20       -0.21      -0.22     Missed  -7.3
 30 2021                                                
 Jun. 30 2021  -0.22       -0.24      -0.24     Met     -1.2​
 Mar. 31 2021  -0.25       -0.25      -0.25     Met     -0.1
 Dec. 31 2020  -0.25       -0.25      -0.26     Missed  -3.6
 This summary was machine generated February 20 at 17:16 GMT. 
All figures in euros  unless otherwise stated